Advisor Group Inc. lifted its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 166,051 shares of the biopharmaceutical company’s stock after buying an additional 20,924 shares during the period. Advisor Group Inc.’s holdings in Gilead Sciences were worth $11,897,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Rowland & Co. Investment Counsel ADV acquired a new position in Gilead Sciences during the 2nd quarter valued at about $153,000. Stonebridge Capital Advisors LLC boosted its stake in Gilead Sciences by 260.6% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 73,943 shares of the biopharmaceutical company’s stock valued at $5,234,000 after purchasing an additional 53,440 shares during the period. Scotia Capital Inc. boosted its stake in Gilead Sciences by 9.8% during the 2nd quarter. Scotia Capital Inc. now owns 146,411 shares of the biopharmaceutical company’s stock valued at $10,362,000 after purchasing an additional 13,078 shares during the period. Linscomb & Williams Inc. boosted its stake in Gilead Sciences by 10.1% during the 2nd quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 531 shares during the period. Finally, Chiron Investment Management LLC boosted its stake in Gilead Sciences by 42.9% during the 2nd quarter. Chiron Investment Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock valued at $18,863,000 after purchasing an additional 80,000 shares during the period. 78.35% of the stock is owned by institutional investors and hedge funds.
GILD has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a research note on Friday, February 23rd. BMO Capital Markets upped their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Finally, Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research note on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $88.61.
GILD stock opened at $74.69 on Tuesday. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The company has a market cap of $98,075.59, a PE ratio of 8.73, a PEG ratio of -1.73 and a beta of 1.18.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The firm’s revenue was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences will post 6.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.05%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 26.64%.
In other news, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares in the company, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. Insiders have sold 308,600 shares of company stock worth $24,328,226 in the last 90 days. 1.16% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Advisor Group Inc. Acquires 20,924 Shares of Gilead Sciences (GILD)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/advisor-group-inc-acquires-20924-shares-of-gilead-sciences-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.